221 related articles for article (PubMed ID: 26962066)
21. The incidence and prevalence of fibromyalgia are higher in multiple sclerosis than the general population: A population-based study.
Marrie RA; Yu BN; Leung S; Elliott L; Warren S; Wolfson C; Tremlett H; Blanchard J; Fisk JD;
Mult Scler Relat Disord; 2012 Oct; 1(4):162-7. PubMed ID: 25877264
[TBL] [Abstract][Full Text] [Related]
22. Differing trends in the incidence of vascular comorbidity in MS and the general population.
Marrie RA; Fisk J; Tremlett H; Wolfson C; Warren S; Blanchard J; Patten SB;
Neurol Clin Pract; 2016 Apr; 6(2):120-128. PubMed ID: 27104065
[TBL] [Abstract][Full Text] [Related]
23. The incidence and prevalence of thyroid disease do not differ in the multiple sclerosis and general populations: a validation study using administrative data.
Marrie RA; Yu BN; Leung S; Elliott L; Warren S; Wolfson C; Tremlett H; Fisk J; Blanchard J
Neuroepidemiology; 2012; 39(2):135-42. PubMed ID: 22889755
[TBL] [Abstract][Full Text] [Related]
24. Multiple sclerosis is associated with higher comorbidity and health care resource use: A population-based, case-control study in a western Mediterranean region.
Cárdenas-Robledo S; Otero-Romero S; Passarell-Bacardit MA; Carbonell-Mirabent P; Sastre-Garriga J; Montalban X; Tintoré M
Eur J Neurol; 2021 Dec; 28(12):4124-4134. PubMed ID: 34293826
[TBL] [Abstract][Full Text] [Related]
25. Change and onset-type differences in the prevalence of comorbidities in people with multiple sclerosis.
Lo LMP; Taylor BV; Winzenberg T; Palmer AJ; Blizzard L; van der Mei I
J Neurol; 2021 Feb; 268(2):602-612. PubMed ID: 32880720
[TBL] [Abstract][Full Text] [Related]
26. PSYCHIATRIC DISORDERS IN THE COURSE OF MULTIPLE SCLEROSIS.
Główczyński P; Błachut M; Zając M; Badura Brzoza KA
Wiad Lek; 2020; 73(8):1780-1784. PubMed ID: 33055351
[TBL] [Abstract][Full Text] [Related]
27. Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases.
Marrie RA; Walld R; Bolton JM; Sareen J; Patten SB; Singer A; Lix LM; Hitchon CA; El-Gabalawy R; Katz A; Fisk JD; Bernstein CN;
Gen Hosp Psychiatry; 2018; 53():65-72. PubMed ID: 29929117
[TBL] [Abstract][Full Text] [Related]
28. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.
Zhang T; Tremlett H; Leung S; Zhu F; Kingwell E; Fisk JD; Bhan V; Campbell TL; Stadnyk K; Yu BN; Marrie RA;
Neurology; 2016 Apr; 86(14):1287-1295. PubMed ID: 26944268
[TBL] [Abstract][Full Text] [Related]
29. Common comorbidities in women and men with epilepsy and the relationship between number of comorbidities and health plan paid costs in 2010.
Wilner AN; Sharma BK; Soucy A; Thompson A; Krueger A
Epilepsy Behav; 2014 Mar; 32():15-20. PubMed ID: 24463303
[TBL] [Abstract][Full Text] [Related]
30. Psychiatric comorbidities in patients with hypertension--a study of registered diagnoses 2009-2013 in the total population in Stockholm County, Sweden.
Sandström YK; Ljunggren G; Wändell P; Wahlström L; Carlsson AC
J Hypertens; 2016 Mar; 34(3):414-20; discussion 420. PubMed ID: 26766563
[TBL] [Abstract][Full Text] [Related]
31. Use of Benzodiazepines and Z-Drugs in Multiple Sclerosis.
Marrie RA; Fisk JD; Walld R; Bolton JM; Sareen J; Patten SB; Singer A; Lix LM; Hitchon CA; El-Gabalawy R; Katz A; Marriott JJ; Bernstein CN;
Front Neurol; 2022; 13():874724. PubMed ID: 35493810
[TBL] [Abstract][Full Text] [Related]
32. Health care utilization before and after intensive care unit admission in multiple sclerosis.
Marrie RA; Bernstein CN; Peschken CA; Hitchon CA; Chen H; Fransoo R; Garland A
Mult Scler Relat Disord; 2015 Jul; 4(4):296-303. PubMed ID: 26195046
[TBL] [Abstract][Full Text] [Related]
33. The prevalence of comorbidities in patients with multiple sclerosis: population-based registry data.
Maric GD; Pekmezovic TD; Mesaros ST; Tamas OS; Ivanovic JB; Martinovic VN; Andabaka MM; Jovanovic AL; Veselinovic ND; Kisic-Tepavcevic DB; Drulovic JS
Neurol Sci; 2021 May; 42(5):1887-1893. PubMed ID: 32964347
[TBL] [Abstract][Full Text] [Related]
34. Comorbidity increases the risk of hospitalizations in multiple sclerosis.
Marrie RA; Elliott L; Marriott J; Cossoy M; Tennakoon A; Yu N
Neurology; 2015 Jan; 84(4):350-8. PubMed ID: 25540309
[TBL] [Abstract][Full Text] [Related]
35. Increased incidence and prevalence of psoriasis in multiple sclerosis.
Marrie RA; Patten SB; Tremlett H; Wolfson C; Leung S; Fisk JD
Mult Scler Relat Disord; 2017 Apr; 13():81-86. PubMed ID: 28427708
[TBL] [Abstract][Full Text] [Related]
36. Somatic comorbidity of epilepsy in the general population in Canada.
Téllez-Zenteno JF; Matijevic S; Wiebe S
Epilepsia; 2005 Dec; 46(12):1955-62. PubMed ID: 16393162
[TBL] [Abstract][Full Text] [Related]
37. Psychiatric co-morbidity in multiple sclerosis: The risk of depression and anxiety before and after MS diagnosis.
Hoang H; Laursen B; Stenager EN; Stenager E
Mult Scler; 2016 Mar; 22(3):347-53. PubMed ID: 26041803
[TBL] [Abstract][Full Text] [Related]
38. The risk of Bipolar Disorders in Multiple Sclerosis.
Carta MG; Moro MF; Lorefice L; Trincas G; Cocco E; Del Giudice E; Fenu G; Colom F; Marrosu MG
J Affect Disord; 2014 Feb; 155():255-60. PubMed ID: 24295600
[TBL] [Abstract][Full Text] [Related]
39. Exploring the role of physical activity and exercise for managing vascular comorbidities in people with multiple sclerosis: A scoping review.
Ewanchuk BW; Gharagozloo M; Peelen E; Pilutti LA
Mult Scler Relat Disord; 2018 Nov; 26():19-32. PubMed ID: 30216755
[TBL] [Abstract][Full Text] [Related]
40. Common psychiatric and metabolic comorbidity of adult attention-deficit/hyperactivity disorder: A population-based cross-sectional study.
Chen Q; Hartman CA; Haavik J; Harro J; Klungsøyr K; Hegvik TA; Wanders R; Ottosen C; Dalsgaard S; Faraone SV; Larsson H
PLoS One; 2018; 13(9):e0204516. PubMed ID: 30256837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
